Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1634 1638
This examiner grants 32% of resolved cases
Vyoma Shubham Tiwari is an examiner in Art Unit 1633 of Tech Center 1600. The examiner has a sample size of 54 resolved cases. The allowance rate is 31.5 percent, which represents the frequency of grants for applications reaching a final resolution. This 31.5 percent rate indicates a challenging path to issuance for applications assigned to this examiner.
However, the data shows an interview lift of 48.1 percent. This 48.1 percent lift suggests that the probability of success increases after an interview. For practitioners, this lift makes an interview a critical step in the prosecution process with Tiwari. Direct communication may help overcome rejections and improve the 31.5 percent baseline allowance rate.
The median days to allowance is 1486, indicating the duration of the prosecution cycle. This 1486-day timeline, combined with the 54 resolved cases, requires a strategic approach. The 48.1 percent interview lift remains a tool for attorneys seeking to navigate the process and secure a patent grant in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18912410 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | Final Rejection | The Regents of the University of California |
| 17607354 | BEAD-FREE EX-VIVO EXPANSION OF HUMAN REGULATORY T CELLS | Final Rejection | The Regents of the University of California |
| 18715678 | ISLET-LIKE ORGANOID EXPRESSING MONSTIM1 IN WHICH INSULIN SECRETION IS REGULATED BY OPTICAL STIMULATION | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18713030 | TUMOR TISSUE MODEL FOR CULTURING TUMOR TISSUE | Non-Final OA | Industry-Academic Cooperation Foundation, Yonsei University |
| 16929948 | High Specificity Genome Editing Using Chemically Modified Guide RNAs | Final Rejection | Agilent Technologies, Inc. |
| 18839402 | HIGH-CONTRAST EN-BLOC STAINING OF MOUSE WHOLE-BRAIN AND HUMAN BRAIN SAMPLES FOR EM-BASED CONNECTOMICS | Non-Final OA | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. |
| 16768462 | MAINTENANCE-AND-AMPLIFICATION METHOD AND DIFFERENTIATION INDUCTION METHOD FOR PRIMORDIAL GERM CELLS/PRIMORDIAL GERM CELL-LIKE CELLS | Final Rejection | KYOTO UNIVERSITY |
| 18726764 | GLUCAGON PROMOTER FOR DIABETES GENE THERAPY | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17822183 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Final Rejection | KSQ Therapeutics, Inc. |
| 17802080 | METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES | Final Rejection | KSQ Therapeutics, Inc, |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy